Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva as adjuvant chemoprevention in high-risk head and neck cancer
NCT00570232Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Dec 2007
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Alabama at Birmingham. Started Dec 2007; status: completed.
02
Drugs
erlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00570232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570232.